Atypical Hemolytic Uremic Syndrome (aHUS) Market

The atypical hemolytic uremic syndrome (aHUS) market has been comprehensively analyzed in IMARC's new report titled "Atypical Hemolytic Uremic Syndrome (aHUS) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Atypical hemolytic uremic syndrome (aHUS) is a rare but severe disorder characterized by the abnormal activation of the complement system, leading to microvascular thrombosis, hemolysis, and kidney injury. Its etiology often involves genetic mutations affecting complement regulatory proteins. Common symptoms include microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, with patients experiencing fatigue, pallor, and decreased urine output. The absence of prodromal diarrheal symptoms distinguishes aHUS from its more common counterpart. The diagnosis of this ailment is challenging, often requiring a thorough clinical evaluation, genetic testing, and complement pathway assessments. Identifying underlying genetic mutations can help in guiding treatment decisions, as aHUS is associated with an increased risk of recurrence.

The escalating incidence of somatic mutations affecting genes associated with the complement pathway, particularly mutations in factors such as factor H, factor I, and membrane cofactor protein, is primarily driving the atypical hemolytic uremic syndrome (aHUS) market. In addition to this, the inflating utilization of advanced medications, including complement inhibitors like eculizumab, to effectively manage aHUS and mitigate the risk of life-threatening complications, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, such as plasma exchange and infusion, which play a pivotal role in addressing the underlying complement dysregulation, is further bolstering the market growth. These therapies aim to restore a balance in the complement system and prevent further renal damage. Apart from this, the rising trend of personalized medicine in aHUS treatment, tailoring therapeutic approaches based on individual patient profiles and genetic factors is acting as another significant growth-inducing factor. Additionally, the increasing recognition of the importance of multidisciplinary care involving nephrologists, hematologists, and other specialists in managing the underlying ailment is expected to drive the atypical hemolytic uremic syndrome (aHUS) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the atypical hemolytic uremic syndrome (aHUS) market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for atypical hemolytic uremic syndrome (aHUS) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the atypical hemolytic uremic syndrome (aHUS) market in any manner.

Recent Developments:

• In May 2024, the U.S. FDA approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
• In October 2023, Alexion Pharma Canada Corp. signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for the treatment of adult and paediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Key Highlights:

• Atypical hemolytic uremic syndrome (aHUS) accounts for 5-10% of HUS occurrences in children and the majority in adults.
• The estimated incidence in Europe is 1/100,000.
• In the United States, approximately 150 to 200 persons may develop aHUS each year.
• aHUS affects people of all ages, with almost half of the cases occurring before the age of 18.
• In childhood, aHUS affects males and females equally, but in adulthood, females are affected more frequently than males, most likely due to pregnancy.

Drugs:

Soliris (eculizumab) is a first-in-class C5 complement inhibitor. The medicine inhibits the C5 protein in the terminal complement cascade, which is part of the body's immune system. When activated in an uncontrolled manner, the terminal complement cascade overreacts, causing the body to attack its healthy cells. Soliris is given intravenously every two weeks after an introductory dosage period.

Crovalimab is an anti-C5 recycling antibody developed using Chugai's Recycling Antibody technology. Recycling antibodies are designed to produce pH-dependent antigen binding, allowing a single antibody molecule to engage with the antigen several times, resulting in greater efficacy than a normal antibody. Crovalimab is intended to target C5, a critical component of the complement system, and is thought to regulate complement activity. By administering it subcutaneously, it will also help to reduce the treatment load on patients and caregivers.

Iptacopan, an oral medication, could be an effective and safe treatment for atypical hemolytic uremic syndrome (aHUS). It is a small-molecule inhibitor of complement factor B, which blocks the creation of the alternative pathway, C3-convertase (C3bBb).

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the atypical hemolytic uremic syndrome (aHUS) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the atypical hemolytic uremic syndrome (aHUS) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current atypical hemolytic uremic syndrome (aHUS) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report:

Market Insights

• How has the atypical hemolytic uremic syndrome (aHUS) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the atypical hemolytic uremic syndrome (aHUS) market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the atypical hemolytic uremic syndrome (aHUS) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of atypical hemolytic uremic syndrome (aHUS) across the seven major markets?
• What is the number of prevalent cases (2018-2034) of atypical hemolytic uremic syndrome (aHUS) by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of atypical hemolytic uremic syndrome (aHUS) by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with atypical hemolytic uremic syndrome (aHUS) across the seven major markets?
• What is the size of the atypical hemolytic uremic syndrome (aHUS) patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of atypical hemolytic uremic syndrome (aHUS)?
• What will be the growth rate of patients across the seven major markets?
   

Atypical Hemolytic Uremic Syndrome (aHUS): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for atypical hemolytic uremic syndrome (aHUS) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the atypical hemolytic uremic syndrome (aHUS) market?
• What are the key regulatory events related to the atypical hemolytic uremic syndrome (aHUS) market?
• What is the structure of clinical trial landscape by status related to the atypical hemolytic uremic syndrome (aHUS) market?
• What is the structure of clinical trial landscape by phase related to the atypical hemolytic uremic syndrome (aHUS) market?
• What is the structure of clinical trial landscape by route of administration related to the atypical hemolytic uremic syndrome (aHUS) market?